The Role of C-reactive Protein in Patient Risk Stratification and Treatment
Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-07-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.49 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846122486689693696 |
|---|---|
| author | Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas |
| author_facet | Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas |
| author_sort | Ramón Arroyo-Espliguero |
| collection | DOAJ |
| description | Atherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this risk. Moreover, the identification of new therapeutic targets will allow the development of drugs that can help reduce the high residual risk of recurrence of cardiovascular events in patients with coronary artery disease. The clinical benefits of reducing recurrent major cardiovascular events recently shown by canakinumab and colchicine have renewed the cardiology community’s interest in inflammation as an aetiopathogenic mechanism for atherosclerosis. This review explores the use of C-reactive protein, which is the most frequently studied biomarker in this context; the concept of residual risk in primary and secondary cardiovascular prevention; and the current recommendations in international guidelines regarding the role of this inflammatory biomarker in cardiovascular risk stratification. |
| format | Article |
| id | doaj-art-acd02d4c12464c03a725034e018e8fd6 |
| institution | Kabale University |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2021-07-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-acd02d4c12464c03a725034e018e8fd62024-12-14T16:02:49ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-07-011610.15420/ecr.2020.49The Role of C-reactive Protein in Patient Risk Stratification and TreatmentRamón Arroyo-Espliguero0María C Viana-Llamas1Alberto Silva-Obregón2Pablo Avanzas3Department of Cardiology, Hospital Universitario de Guadalajara, Guadalajara, SpainDepartment of Cardiology, Hospital Universitario de Guadalajara, Guadalajara, SpainDepartment of Intensive Medicine, Hospital Universitario de Guadalajara, Guadalajara, SpainDepartment of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain; Department of Medicine, Universidad de Oviedo, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, SpainAtherosclerosis is a chronic inflammatory disease. Several circulating inflammatory markers have been proposed for clinical use due to their ability to predict future cardiovascular events and may be useful for identifying people at high risk who might benefit from specific treatment to reduce this risk. Moreover, the identification of new therapeutic targets will allow the development of drugs that can help reduce the high residual risk of recurrence of cardiovascular events in patients with coronary artery disease. The clinical benefits of reducing recurrent major cardiovascular events recently shown by canakinumab and colchicine have renewed the cardiology community’s interest in inflammation as an aetiopathogenic mechanism for atherosclerosis. This review explores the use of C-reactive protein, which is the most frequently studied biomarker in this context; the concept of residual risk in primary and secondary cardiovascular prevention; and the current recommendations in international guidelines regarding the role of this inflammatory biomarker in cardiovascular risk stratification.https://www.ecrjournal.com/articleindex/ecr.2020.49 |
| spellingShingle | Ramón Arroyo-Espliguero María C Viana-Llamas Alberto Silva-Obregón Pablo Avanzas The Role of C-reactive Protein in Patient Risk Stratification and Treatment European Cardiology Review |
| title | The Role of C-reactive Protein in Patient Risk Stratification and Treatment |
| title_full | The Role of C-reactive Protein in Patient Risk Stratification and Treatment |
| title_fullStr | The Role of C-reactive Protein in Patient Risk Stratification and Treatment |
| title_full_unstemmed | The Role of C-reactive Protein in Patient Risk Stratification and Treatment |
| title_short | The Role of C-reactive Protein in Patient Risk Stratification and Treatment |
| title_sort | role of c reactive protein in patient risk stratification and treatment |
| url | https://www.ecrjournal.com/articleindex/ecr.2020.49 |
| work_keys_str_mv | AT ramonarroyoespliguero theroleofcreactiveproteininpatientriskstratificationandtreatment AT mariacvianallamas theroleofcreactiveproteininpatientriskstratificationandtreatment AT albertosilvaobregon theroleofcreactiveproteininpatientriskstratificationandtreatment AT pabloavanzas theroleofcreactiveproteininpatientriskstratificationandtreatment AT ramonarroyoespliguero roleofcreactiveproteininpatientriskstratificationandtreatment AT mariacvianallamas roleofcreactiveproteininpatientriskstratificationandtreatment AT albertosilvaobregon roleofcreactiveproteininpatientriskstratificationandtreatment AT pabloavanzas roleofcreactiveproteininpatientriskstratificationandtreatment |